ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ziltivekimab

Also written as “Ziltivekimab”, “Ziltivekimab B” and “Ziltivekimab C”.

Its studies are mostly in Renal Insufficiency, Chronic · Heart Failure · Myocardial Infarction · Coronary Artery Disease · Anemia, led by 2 companies.

Drug pageZiltivekimab: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 19, 202112 company-led studies, 4 open or runningNext primary completion: Jan 29, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only113 open or runningphase 3since Aug 19, 2021Mar 19, 2012Jan 29, 2027phase 3 · NCT06118281
ECRI bvits history only11 open or runningphase 3since Nov 28, 2025Nov 28, 2025Sep 1, 2028phase 3 · NCT07276282
  • Named in Novo Nordisk’s own pipeline as Ziltivekimab, phase 3, as of Nov 5, 2026 (source).

Also a collaborator on its studies: Corvidia Therapeutics and Cardialysis.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 19, 2012First study: phase 1 study in Arthritis, RheumatoidNew to Novo NordiskNovo Nordisk · NCT01559103 · 39 enrolled · United States, Germany, United Kingdom
  2. Aug 9, 2016Phase 2 study in AnemiaNovo Nordisk · NCT02868229 · 61 enrolled · United States
  3. Apr 19, 2019Phase 2 study in Renal Insufficiency, ChronicNovo Nordisk · NCT03926117 · 264 enrolled · United States
  4. Jun 9, 2019Named ziltivekimabINNProposed as its International Nonproprietary Name in WHO's List 121 · before, COR-001, MEDI5117
  5. Nov 10, 2020Phase 2 study in Renal Insufficiency, ChronicNovo Nordisk · NCT04626505 · 36 enrolled · Japan
  6. Aug 19, 2021Phase 3 study in Renal Insufficiency, ChronicNovo Nordisk · NCT05021835 · 6,385 enrolled · United States, Argentina, Australia and more
  7. May 15, 2022Phase 1 study in Renal Insufficiency, ChronicNovo Nordisk · NCT05379829 · 24 enrolled · China
  8. Nov 23, 2022Phase 3 study in Heart FailureNovo Nordisk · NCT05636176 · 4,874 enrolled · United States, Argentina, Australia and more
  9. Feb 1, 2023Phase 1 study in Healthy ParticipantsNovo Nordisk · NCT05721989 · 267 enrolled · Hungary, Netherlands
  10. Oct 31, 2023Phase 3 study in Cardiovascular RiskNovo Nordisk · NCT06118281 · 10,000 enrolled · United States, Argentina, Australia and more
  11. Dec 28, 2023Phase 3 study in Heart FailureNovo Nordisk · NCT06200207 · 673 enrolled · United States, Argentina, Australia and more
  12. Nov 27, 2025Phase 3 study in Myocardial InfarctionNovo Nordisk · NCT07301034 · 332 planned · Austria, Denmark, Italy and more
  13. Nov 28, 2025ECRI bv’s first study: phase 3 study in Coronary Artery DiseaseNew to ECRI bvECRI bv · NCT07276282 · 332 planned · Switzerland

Ahead

  1. Jan 29, 2027Primary completion: phase 3 study in Cardiovascular RiskNovo Nordisk · NCT06118281
  2. Sep 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseECRI bv · NCT07276282
  3. Nov 14, 2028Primary completion: phase 3 study in Myocardial InfarctionNovo Nordisk · NCT07301034

TargetBeta

IL6 →read by rule
“Interleukin-6 inhibitor; Interleukin-6 binding agent”ChEMBL 37, by rule

Other programs on IL6

ProgramCompanyFurthest phaseStudies
olokizumabruleR-Pharmphase 319
clazakizumabCSLphase 310
pacibekitugruleNovartisphase 31
isomyosamineruletnf-pharmaceuticals-incphase 21

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07276282Coronary Artery Disease · Switzerland3RecruitingECRI bvSep 1, 2028332
NCT07301034Myocardial Infarction · Austria, Denmark, Italy and more3RecruitingNovo NordiskNov 14, 2028332
NCT06200207Heart Failure · United States, Argentina, Australia and more3Active, not recruitingNovo NordiskOct 1, 2026673
NCT06118281Cardiovascular Risk · United States, Argentina, Australia and more3Active, not recruitingNovo NordiskJan 29, 202710,000
NCT05721989Healthy Participants · Hungary, Netherlands1CompletedNovo NordiskJan 8, 2024267
NCT05636176Heart Failure · United States, Argentina, Australia and more3TerminatedNovo NordiskSep 3, 20264,874
NCT05379829Renal Insufficiency, Chronic · China1CompletedNovo NordiskJun 12, 202424
NCT05021835Renal Insufficiency, Chronic · United States, Argentina, Australia and more3CompletedNovo NordiskJun 9, 20266,385
NCT04626505Renal Insufficiency, Chronic · Japan2CompletedNovo NordiskAug 3, 202136
NCT03926117Renal Insufficiency, Chronic · United States2CompletedNovo NordiskJun 26, 2020264
NCT02868229Anemia · United States2CompletedNovo NordiskDec 11, 201861
NCT01559103Arthritis, Rheumatoid · United States, Germany, United Kingdom1TerminatedNovo NordiskFeb 28, 201439

How it is read

Names in the registry

  • “Ziltivekimab”, 8 entries
  • “Ziltivekimab B”, 2 entries
  • “Ziltivekimab C”, 2 entries
  • “COR-001”, 1 entry
  • “MEDI5117”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.